Impulse control disorders in Parkinson’s disease: decreased striatal dopamine transporter levels

Valerie Voon,1,2,3 Alexandra Rizos,4 Riddhika Chakravartty,4,5 Nicola Mulholland,4,5 Stephanie Robinson,4 Nicholas A Howell,1,6 Neil Harrison,6 Gill Vivian,5 K Ray Chaudhuri4

ABSTRACT
Objective Impulse control disorders are commonly associated with dopaminergic therapy in Parkinson’s disease (PD). PD patients with impulse control disorders demonstrate enhanced dopamine release to conditioned cues and a gambling task on [11C]raclopride positron emission tomography (PET) imaging and enhanced ventral striatal activity to reward on functional MRI. We compared PD patients with impulse control disorders and age-matched and gender-matched controls without impulse control disorders using [123I]FP-CIT (2β-carbomethoxy-3β-[4-iodophenyl]tropane) single photon emission computed tomography (SPECT), to assess striatal dopamine transporter (DAT) density.

Methods The [123I]FP-CIT binding data in the striatum were compared between 15 PD patients with and 15 without impulse control disorders using independent t tests.

Results Those with impulse control disorders showed significantly lower DAT binding in the right striatum with a trend in the left (right: F(1,24)=5.93, p=0.02; left: F(1,24)=3.75, p=0.07) compared to controls.

Conclusions Our findings suggest that greater dopaminergic striatal activity in PD patients with impulse control disorders may be partly related to decreased uptake and clearance of dopamine from the synaptic cleft. Whether these findings are related to state or trait effects is not known. These findings dovetail with reports of lower DAT levels secondary to the effects of amphetamine and alcohol. Although any regulation of DAT by antiparkinsonian medication appears to be modest, PD patients with impulse control disorders may be differentially sensitive to regulatory mechanisms of DAT expression by dopaminergic medications.

INTRODUCTION
Impulse control disorders (ICDs) are commonly associated with dopaminergic therapy and can occur in over 17% of those on dopamine agonists for Parkinson’s disease (PD).1 The behaviours, including pathological gambling, hypersexuality, binge eating, compulsive shopping and punding, can have significant financial and social consequences.

Why this subset of patients with PD develops these behaviours has been the focus of recent research. Several lines of evidence point towards enhanced striatal dopaminergic activity in PD patients with ICDs as compared to those without ICDs. PD patients with pathological gambling as compared to PD controls show greater ventral striatal dopamine release to a gambling task measured using [11C]raclopride positron emission tomography (PET).2 [11C]raclopride is a ligand-binding D2 and D3 receptors and can provide an index of presynaptic dopamine release or D2/D3 receptor density. In this same study, PD patients with pathological gambling had lower [123I] raclopride binding to a motor control task which the authors interpret as suggesting decreased expression of D2/D3 receptors. Similarly, in response to visual cues, PD patients with mixed ICDs as compared to PD controls have greater ventral striatal and posterior putaminal dopamine release, consistent with a classical cue-conditioning response.3 In contrast to the previous study, there were no differences at baseline between the two groups. PD patients with mixed ICDs also show greater blood oxygen level-dependent ventral striatal activity in functional MRI (fMRI) in a probabilistic learning task to unexpected and expected reward.4 Similarly, PD patients with compulsive medication use or punding symptoms also have enhanced ventral striatal dopamine release to levodopa as measured using [13C]raclopride PET.5

Whether this enhanced detection of striatal dopamine is solely related to greater dopamine release or whether dopamine might also be more likely to remain in the synaptic cleft due to decreased uptake and clearance via the dopamine transporter (DAT) remains unclear. Using [123I]FP-CIT (2β-carbomethoxy-3β-[4-iodophenyl]tropane) single photon emission computed tomography (SPECT), which binds dopamine and serotonin transporters, a small study with 8 PD patients with pathological gambling, 21 matched PD controls and 14 healthy controls demonstrated lower transporter density in the ventral striatum in PD+ICD patients.6 The authors suggest that rather than a reduction in mesolimbic dopaminergic projections, this decrease in DAT density is likely related to a downregulation of striatal DAT, consistent with the previous reports of greater striatal dopamine release. Here, we study a much larger sample size of PD patients with ICDs and compare with age-matched (±5 years) and gender-matched PD controls using [123I]FP-CIT SPECT and hypothesise a decrease in striatal DAT density in PD patients with ICDs.

METHODS
PD subjects were recruited from Kings College Hospital Movement Disorders clinic among patients who underwent routine [123I]FP-CIT SPECT as part of the clinical assessment of PD to detect loss of functional dopaminergic neuron.
slow intravenous injection of 185 MBq (5 mCi) [123I]FP-CIT blockade 24 h prior to the study. Patients were scanned 4 h after medicatations. Oral potassium iodate was administered for thyroid medications. Subjects were continued on their dopaminergic medicine and sertraline. None of the subjects were on these medications, bupropion, cocaine, mazindol, methylphenidate, phentermine and sertraline. None of the subjects were on these medications. Oral potassium iodate was administered for thyroid blockade 24 h prior to the study. Patients were scanned 4 h after a slow intravenous injection of 183 MBq (5 mCi) [123I]FP-CIT (Ioflupane, GE Healthcare, Arlington Heights, Illinois, USA). The 40-min SPECT acquisition was performed with the patient supine on a Philips SKYLight dual-head gamma camera with a low-energy general purpose collimator; the patient’s head in the field of view being lightly restrained as to enable the smallest possible rotational radius. Patients were not sedated for the imaging sequence. Imaging parameters used included a clockwise step and shoot protocol of 40 s for each of the 120 azimuths, a 128×128×16 matrix, a 20% energy window centred at 159 keV with no zoom. After ensuring the absence of patient’s motion and applying motion correction as required, images were reconstructed on a Adac Pegasus workstation using a filtered backprojection algorithm using a Butterworth low-pass filter (order=8, cut-off=0.7). The software program BRAS on Hermes workstation was used to automatically delineate circular regions of interest (ROIs) over the caudate and putamina on the transaxial images and the overall striata on the coronal images. A single ROI over the occipital lobe provides the background (non-specific) uptake area. These ROIs were checked and realigned manually if needed. Quantitation in the form of specific ratios for each caudate/ putamen and the overall striata were calculated as follows:

FP-CIT binding in area of uptake=[(mean counts per pixel in the ROI in area of uptake)−(mean counts per pixel in the occipital cortex)]/(mean counts per pixel in the occipital cortex).

These ratios were not adjusted for age or gender. The images were viewed on a workstation by an experienced nuclear physician blinded to the ICD status to assess the overall SPECT binding pattern. Areas of reduced uptake within the striata were reported with description of the intensity and location as well as a comment on the quantitative value. All subjects received informed consent, and the study was approved by the local research ethics committee.

**Statistics**

The binding data were compared between PD+ICD and PD−ICD groups. Parametric tests were used after the data were tested for normal distribution using Shapiro–Wilk test. The subject characteristics were compared using independent t tests. The binding data in the right and left caudate and putamen were then compared using multivariate analyses between groups.

**RESULTS**

Fifteen PD+ICD subjects were compared with 15 age-matched and gender-matched PD−ICD controls. There were no differences in gender, age, PD duration, H+Y score or dopaminergic medication dose calculated as levodopa dose equivalence between the groups (table 1). In the PD+ICD group, 13/14 were on dopamine agonists (pramipexole=4, ropinirole=8, rotigotine=2) at the time of their ICD symptoms with one subject on amantadine. The PD+ICD DAT binding data of one subject was not included as the scores were outliers (score >3 SD above group mean).

Compared to PD−ICD subjects, PD+ICD patients had lower DAT binding in bilateral striatum (table 2 and figure 1). Although there were no differences in age or PD duration between groups, since age and PD duration are known to affect DAT expression, the group differences were also compared with univariate analysis using age and PD duration as covariates of no interest. The difference in the right striatum remained significantly different in PD+ICD patients when covariated for age and PD duration with a trend in the left striatum (right: F(1,24) =5.93, p=0.02; left: F(1,24)=3.75, p=0.07). The different

### Table 1 Subject and disease characteristics

|                | PD−ICD | PD+ICD | df | t   | p   |
|----------------|--------|--------|----|-----|-----|
| N              | 15     | 15     |    |     |     |
| Gender in No males (%) | 9 (60) | 9 (60) |    |     |     |
| Age in years old | 60.13 (7.98) | 55.07 (8.91) | 28 | 1.61 | 0.12 |
| PD duration in years | 5.53 (5.21) | 7.54 (5.39) | 28 | −0.99 | 0.33 |
| Median H+Y score | 3.00 | 3.00 | 28 | 0.19 | 0.86 |
| Total LEDD in mg/d (n) | 852.15 (520.37) | 785.80 (402.73) | 26 | 0.32 | 0.75 |
| (14) | (13) |
| No of dopamine agonist | 10 | 13 |     |     |     |
| Dopamine agonist LEDD in mg/d | 384.33 (212.85) | 325.77 (156.10) | 22 | 0.07 | 0.94 |
| Behaviours | CS: 5 | HS: 4 | PG: 3 | Punding/hobbyism: 6 |

All values reported as mean (SD) unless otherwise indicated.

CS, compulsive shopping; HS, hypersexuality; ICD, impulse control disorders; LEDD, levodopa dose daily equivalent; mg/d, milligrams/day; n, number of subjects; PD, Parkinson’s disease; PG, pathological gambling.

Voon V, et al. J Neurol Neurosurg Psychiatry 2014; 85:148–152. doi:10.1136/jnnp-2013-305395
striatal regions were also compared using a multivariate analysis using age and PD duration as covariates of no interest: the right caudate (F(1,24)=8.19, p=0.006), right putamen (F(1,24)=6.60, p=0.02) and right putamen (F(1,24)=4.59, p=0.04) remained significant with a trend towards significance in the left caudate (F(1,24)=4.18, p=0.052).

The binding data of the different striatal regions of the behaviour were then compared between PD−ICD, PD+ICD (n=9) and punding only (n=5) using multivariate analyses. There were significant differences in the right caudate (F(2,24)=3.65, p=0.04) and right putamen (F(2,24)=3.64, p=0.04) but not in the left caudate (F(2,24)=1.83, p=0.18) or the left putamen (F(2,24)=2.48, p=0.10) (figure 1). PD+ICD had significantly lower DAT binding compared to PD−ICD in the right caudate (mean difference 0.76 (SEM 0.28), p=0.01) and right putamen (0.64 (SEM 0.24), p=0.01) on post hoc analyses with no other significant differences documented.

**DISCUSSION**

We show that PD+ICD patients have lower striatal DAT levels relative to matched PD−ICD controls with similar Hoehn and Yahr stage severity. Dopamine reuptake via the sodium chloride-dependent DAT, a membrane-spanning protein located in the axon terminals, is the primary mechanism by which striatal dopamine is removed from the synaptic cleft and dopamine neurotransmission regulated and terminated. These findings may help explain the observation of enhanced ventral striatal activity and enhanced dopamine release in PD+ICD patients. In response to conditioned cues or to a gambling task, PD+ICD patients demonstrate increased ventral striatal dopamine release

as measured using [123I]raclopride. Similarly in response to conditioned cues or to unexpected and anticipated rewards, PD+ICD patients demonstrated increased ventral striatal activity.1 4 9 Our findings suggest that one possible explanation for the enhanced dopaminergic activity is that impaired clearance of dopamine may play a role in extending the physiological effect of dopamine at the synaptic terminal. This finding extends previous observations of lower DAT ventral striatal expression in a smaller sample size of PD and gambling patients.6

Our findings also suggest that DAT density may be decreased in PD+ICD subjects but this observation may not hold for those with punding behaviours. In the subanalysis, the differences between PD+ICD and PD−ICD remained significant and there were no differences in DAT binding between those with punding/hobbyism and PD−ICD. Punding has been associated with levodopa10 rather than dopamine agonists and underlying mechanisms may differ from that of ICDs. Although our sample size of subjects with punding/hobbyism (n=5) was too small to draw any conclusions, our preliminary findings are indicative of differences between ICDs and punding.

The binding levels of [123I]FP-CIT may reflect either lower DAT levels or greater dopaminergic nerve terminal degeneration. There is no clear clinical evidence for a greater decrease in dopaminergic terminals in PD+ICD patients relative to PD controls. In a large multicenter study, motor severity as measured using UPDRS III or H+Y staging was not different between PD+ICD and PD−ICD controls suggesting similar putaminal dopaminergic nerve terminal density.1 11 However, the association of PD+ICD with greater levodopa dose1 suggests possibly the necessity for higher levodopa doses to maintain a similar level of motor functioning. As discussed, several lines of evidence have shown greater ventral striatal dopaminergic release to incentive cues and a gambling task and enhanced ventral striatal activity to reward.2 4 PD patients with mixed ICDs have also been shown to have a 35% increase in [18F]fluorodopa uptake in the medial orbitofrontal cortex with no differences in striatal uptake compared to PD controls. Together, these findings suggest that rather than the lower binding levels of [123I]FP-CIT reflecting greater dopaminergic nerve terminal degeneration and hence lower dopaminergic activity, this suggests that the lower binding levels might either reflect greater sensitivity to medication-related DAT downregulation or baseline trait differences and hence higher dopaminergic activity. Lower DAT levels with similar nerve terminal density suggest that extracellular dopamine neurotransmission can be enhanced in distance from the synaptic cleft and duration of action.

---

**Table 2** Binding values

| Region           | PD−ICD | PD+ICD | Error | F   | p Value |
|------------------|--------|--------|-------|-----|---------|
| R striatum       | 1.43 (0.68) | 0.91 (0.41) | 27    | 6.22 | 0.02    |
| L striatum       | 1.45 (0.67) | 0.98 (0.47) | 27    | 4.87 | 0.04    |
| R caudate        | 1.68 (0.71) | 1.06 (0.63) | 27    | 6.12 | 0.02    |
| L caudate        | 1.57 (0.60) | 1.13 (0.62) | 27    | 3.77 | 0.06    |
| R putamen        | 1.14 (0.68) | 0.63 (0.41) | 27    | 5.80 | 0.02    |
| L putamen        | 1.23 (0.75) | 0.70 (0.48) | 27    | 5.14 | 0.03    |
| R caudate:putamen ratio | 1.70 (0.55) | 1.78 (0.57) | 27    | 0.15 | 0.71    |
| L caudate:putamen ratio | 1.54 (0.56) | 1.81 (0.61) | 27    | 1.45 | 0.24    |

All values reported as mean (SD).
There are several reasons why DAT binding may be decreased. In PD+ICD subjects, there may be underlying differences in genetic expression of DAT or alternatively, an interaction between dopaminergic medications and DAT regulation. For instance, differences in the variable number tandem repeat at the 3' end of the gene for DAT, DAT1, can affect basal transporter expression. However, in a small study, no differences in DAT1 polymorphisms were noted between PD+ICD (n=41) and PD controls.12

Alternatively, multiple substances of abuse, such as methamphetamine, cocaine and alcohol, can differentially affect the regulation of DAT. For instance, methamphetamine is associated with decreased DAT density as measured using PET imaging and DAT ligands.13 14 This decrease in DAT density has been shown in early abstinence (<6 months) with some degree of recovery after prolonged abstinence (12–16 months).15 However, given that cognitive deficits persist following prolonged abstinence from methamphetamine, the partial recovery was not suggested to be functionally sufficient.16 Similarly, alcohol-dependent subjects in early abstinence during detoxification and withdrawal have lower DAT levels as measured using [123I]FP-CIT SPECT, which normalises at 4 weeks of abstinence.17 In contrast, cocaine, which acts directly to inhibit DAT, increases DAT in early abstinence as measured using [99mTc]TRODAT and [123I]FP-CIT SPECT18–19 consistent with findings in postmortem studies. This observation may also play a mechanistic role in the behavioural responses observed in PD+ICD subjects. For instance, in cocaine dependence, which acts through DAT inhibition with subsequent increases in dopamine levels, the degree of DAT occupancy is associated with the subjective experience of a ‘high’.20

In contrast to the effects of substances of abuse, the effects of levodopa or dopamine agonists on DAT regulation in PD are less pronounced. Short-term 6-week administration of either levodopa (~16% to ~22%) or pramipexole (~15% to ~20%) in early PD has been shown to modestly downregulate DAT compared to placebo (~12%) as measured using [11C]RTI-32 PET imaging.21 In contrast, short-term 6-week pergolide co-administration with levodopa for dyskinesia in PD patients was associated with a trend towards DAT upregulation (8%) as measured using [123I]FP-CIT SPECT.22 The trend normalised following a 4-week pergolide washout. Short-term 6-week treatment with levodopa did not demonstrate any differences in DAT binding in early PD as measured using [123I]FP-CIT SPECT.23 Thus, DAT regulation by levodopa or dopamine agonists, if any, appears to be modest and its effect might be dependent on its use in early versus late PD or as monotherapy versus co-therapy. Although any regulation of DAT by antiparkinsonian medications appears to be modest, PD+ICD patients may be differentially sensitive to regulatory mechanisms of DAT expression (eg, D2 autoreceptor, TAAR1, protein kinase A and C, reviewed in ref. 24) compared to PD controls. A mechanism implicating DAT downregulation would also suggest that symptom improvement following discontinuation of the dopamine agonist would have a delayed timecourse. This may also play a role in the observation of enhanced dopamine withdrawal symptoms observed following dopamine agonist discontinuation in PD patients with ICDs.25

Although we focus here on DAT levels and the role of impaired clearance from the synaptic cleft, other dopamine regulatory mechanisms may also be implicated in the observation of enhanced dopaminergic activity in PD+ICD patients.26 Although acute dopamine agonist (pramipexole) administration in rodents has been shown to decrease the proportion of spontaneously firing dopaminergic neurons, chronic dopamine agonists normalise this proportion of firing neurons mediated via D2/D3 autoreceptor downregulation.27 Furthermore, chronic levodopa administration in a Parkinsonian rodent model has been shown to increase the proportion of spontaneously firing dopaminergic neurons, secondary to D2/D3 autoreceptor downregulation.28 These spontaneously firing dopaminergic neurons are the neurons that are capable of phasic activity in response to a stimulus (eg, the unconditioned rewarding stimulus, conditioned stimulus, a gambling task).29 Thus, increasing the proportion of spontaneously firing neurons effectively increases the gain and proportion of dopamine neurons capable of phasically responding to a stimulus. Preliminary evidence exists that PD patients with ICDs have decreased sensitivity of the D2/D3 autoreceptor in the midbrain as measured using [11C]FLB-457 PET.30 In this study, PD controls on dopamine agonists demonstrated decreased D2/D3 midbrain autoreceptor binding to a gamble task as compared to a control task, consistent with the feedback regulation of endogenous dopamine released in the gamble task. In contrast, PD patients with ICDs on dopamine agonists failed to demonstrate a difference suggesting decreased sensitivity of the D2/D3 autoreceptor. Thus, the enhanced dopamine levels observed in PD+ICD may be related to impaired regulatory feedback.

In the striatum, DAT is localised to the plasma membranes of axon varicosities and terminals that contain synaptic vesicles, thus supporting its role in regulating and terminating extracellular dopamine activity occurring via synaptic vesicular release.31 DAT is also localised to non-synaptic region which may play a role in regulation of extracellular dopamine associated with volume transmission in which dopamine may diffuse to act functionally across long ranges.32 DAT localisation in a non-synaptic region may also play a role in regulating dopamine activity associated with reverse transport of dopamine through the plasma membrane, a mechanism implicated in the actions of amphetamines.33 34 β-CIT is likely measuring plasmalemmal rather than intracellular DAT. In primates, β-CIT is dramatically reduced following amphetamine. Since amphetamine is a substrate of DAT, the observed reduced binding is likely reflecting DAT internalisation suggesting that β-CIT does not bind significantly to internalised DAT or that internalised DAT has lower binding affinity to β-CIT.35

This study is limited by the small sample size and mixed ICDs. Larger studies specifically focusing on punding behaviours may be indicated to differentiate underlying mechanisms from ICDs. As the study is cross sectional, we cannot determine whether the decreased DAT is secondary to the dopaminergic medication or is a predisposing risk factor. Further research focusing on subtype differences or longitudinal studies is indicated. Assessing the relative contribution of sensitivity of the D2 autoreceptor and DAT levels to the enhanced release of dopamine would also be indicated.

We show that PD+ICD subjects have lower DAT binding compared to PD–ICD subjects. An effect on DAT regulation is consistent with observations in substance use disorders. Decreased reuptake may account for some of the enhancement in dopamine activity beyond that of dopamine release and may also contribute to the behavioural effects.

Contributors VV, AR and KRC were responsible for the conception and design, or analysis and interpretation of data, drafting the article and revising it critically for important intellectual content and final approval of the version to be published. RC, NM, SR NAH, NH and GV were responsible for analysis and interpretation of data, revising it critically for important intellectual content and final approval of the version to be published.

Funding This paper presents independent research funded by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King’s College
Neuropsychiatry

London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Wellcome Trust grant number WT093705MA.

Competing interests KRC is a consultant for Mundipharma, UCB Pharma, Medtronic, Boehringer Ingleheim, Britannia and Abbott. He has received research support from UCB Pharma, Boehringer Ingleheim and Abbott. He has received honoraria from Mundipharma, UCB Pharma, Medtronic, Boehringer Ingleheim, Britannia, Abbott, Teva, Otsuka, VV, AR, RC, NM, SR, NAH, NH and VG do not have any conflict of interests to declare.

Ethics approval Local Research Ethics Committee (adopted by NIHR).

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES

1. Weintraub D, Koester I, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589–95.
2. Steeves TD, Miyasaki J, Zurovski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009;132:1376–85.
3. O’Sullivan SS, Wu K, Politis M, et al. Cue-induced striatal dopamine release in Parkinson’s disease-associated impulsive-compulsive behaviours. Brain 2011;134:969–78.
4. Voon V, Persiglione M, Brezing C, et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 2010;65:135–42.
5. Evans AH, Pawse N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006;59:852–8.
6. Cilia R, Ko JH, Cho SS, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson’s disease and pathological gambling. Neurobiol Dis 2010;39:98–104.
7. Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007;64:1089–96.
8. Tomlinson CL, Stone R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010;25:2649–53.
9. Steeves TD, Ko JH, Kideckel DM, et al. Extrastriatal dopaminergic dysfunction in tourette syndrome. Ann Neurol 2010;67:710–81.
10. Evans AH, Katzenschlager R, Pavlov D, et al. Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397–405.
11. Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case–control study. Ann Neurol 2011;69:986–98.
12. Vellalunga A, Flabani R, Formento-Dojot P, et al. Role of genetic polymorphisms of the dopaminergic system in Parkinson’s disease patients with impulse control disorders. Parkinsonism Relat Disord 2012;18:397–9.
13. Sekine Y, Iyo M, Ouchi Y, et al. Methamphetamine-related psychotic symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 2001;158:1206–14.
14. McCann UD, Wong DF, Yokoi F, et al. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 1998;18:9417–22.
15. Volkow ND, Chang L, Wang GI, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001;21:9414–8.
16. Laine TP, Ahonen A, Torniainen P, et al. Dopamine transporters increase in human brain after alcohol withdrawal. Molecular psychiatry. 1996;4:189–91, O4–5.
17. Crits-Christoph P, Neveberg A, Wintenberg N, et al. Dopamine transporter levels in cocaine dependent subjects. Drug Alcohol Depend 2008;98:70–6.
18. Mallison RT, Best SE, van Dyck CH, et al. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry 1998;155:832–4.
19. Jacobsen JK, Staike JK, Mallison RT, et al. Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry 2000;157:1134–40.
20. Volkow ND, Wang GI, Fischman MW, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997;386:827–30.
21. Gottman M, Stewart D, Hussey D, et al. Influence of L-dopa and primapixeole on striatal dopamine transporter in early PD. Neurology 2001;56:1559–64.
22. Ahlskog JE, Uitti R, O’Connor MK, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson’s disease. Mov Disord 1999;14:940–6.
23. Innis RB, Marek KL, Shif F, et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 1999;14:436–42.
24. Schmitt KC, Reith ME. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann NY Acad Sci 2010;1187:316–40.
25. Rabinaik CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67:58–63.
26. Voon V, Fernagut PO, Wickens J, et al. Chronic dopaminergic stimulation in Parkinson’s disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009;8:1140–9.
27. Chemoloz O, El Mansari M, Blier P. Sustained administration of primapixeole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 2009;34:651–61.
28. Harden DG, Grace AA. Activation of dopamine cell firing by repeated L-DOPA administration to dopamine-depleted rats: its potential role in mediating therapeutic response to L-DOPA treatment. J Neurosci 1995;15:6157–66.
29. Grace AA. Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropsychopharmacology 2012;62:1342–8.
30. Ray NJ, Miyasaki JM, Zurovski M, et al. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson’s patients with medication-induced pathological gambling: a [11C] FJ8-457 and PET study. Neurobiol Dis 2012;48:519–29.
31. Nirenberg MJ, Vaughan RA, Uh GR, et al. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 1996;16:436–47.
32. Schneider JS, Rothblat DS, DiStefano L. Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism. Brain Research 1994;643:86–91.
33. Sulzer D, Chen TK, Lau YY, et al. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 1995;15:4102–8.
34. Sulzer D, Sonders MS, Poulsen NW, et al. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005;75:406–33.
35. Laruelle M, Baldwin RM, Malison RT, et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295–309.